Q4 2024 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Key Points
- Sartorius AG (SARTF) achieved its reverse guidance for 2024, with both top-line and profitability meeting expectations.
- The Bioprocess Solutions division saw a slight sales increase, driven by strong growth in the consumables business.
- Order intake for the group was double digits ahead of the prior year, indicating strong demand recovery.
- The company successfully implemented an efficiency program, saving over EUR 100 million and maintaining a robust EBITDA margin.
- Sartorius AG (SARTF) expects to outperform the market with moderate profitable growth in 2025, driven by fundamental growth drivers in the biopharma industry.
- Sales for the Lab Products & Services (LPS) division were slightly below the previous year's level, impacted by a soft market in China.
- The equipment business remained muted, with negative double-digit growth in 2024.
- Profitability was slightly below 2023 levels due to lower capacity utilization and inventory reduction efforts.
- The company remains cautious about the market outlook for 2025, expecting growth below midterm average rates.
- The financial results were impacted by increased depreciation and higher financial expenditures, leading to a lower underlying net profit compared to the prior year.
Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech Conference Call on the preliminary results 2024 conference call and live webcast. I am Yousef, the Chorus Call operator. (Operator Instructions) The conference is being recorded. This call is scheduled for 60 minutes. The presentation will be followed by a Q&A session. (Operator Instructions) The conference was not to be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Joachim Kreuzburg. Please go ahead.
Yeah. Thank you very much for opening our conference call today, and welcome, everyone. Thank you for dialing in. Thank you for your interest in Sartorius and Sartorius Stedim Biotech. As always, we will present our results in a way that I will start with some highlights, and then Florian will expand on the financial results in quite some detail on the Sartorius Group. And then after that, Rene will talk about the results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
